Mesenchymal stem-cell derived treatment in osteosarcoma between 1993-2023: Bibliometric study
Öz
Objective: Osteosarcoma is a malignant bone tumor with a high incidence in adolescence and childhood. Treatment is long and difficult, including chemotherapy, radiotherapy, and orthopedic surgery. Stem cell-derived treatment has also recently been studied in osteosarcoma. In this bibliometric study, we aimed to illuminate the trend of research between osteosarcoma and stem cell-derived treatment.
Materials and Methods: Publications on osteosarcoma were retrieved from the Web of Science Core Collection. R studio software and the VOS viewer analysis program were used for data analysis.
Results: There were 853 publications with an average of 7.7 publications per year. The most productive countries were the USA and China respectively. According to the categorical classification described in the WoS, oncology (41.7%), and cell biology (18.1%) were the first two fields in terms of diagnosis and treatment, while pathology (3.7%) and orthopedics (2.2%) had lower levels of work. However, the most cited author locally was Gibbs from the University of Florida University of Alberta UF Orthopedic & Sports Med Inst. in the USA. The keywords “cancer stem cell”, “bone cancer”, and “mesenchymal stem cell” had been determined to have strong links to osteosarcoma. Cancer Res was the most cited journal.
Conclusion: As a result, it has been found that research presenting strong links to the relationship between cell-derived therapy and osteosarcoma has shown an increase in recent years.
Anahtar Kelimeler
Stem cells, Osteosarcoma, Bibliometrics
Destekleyen Kurum
Yok
Proje Numarası
yok
Etik Beyan
Yok
Teşekkür
yok
Kaynakça
- Choi JH, Ro JY. The 2020 WHO Classification of Tumors of Bone: An Updated Review. Adv Anat Pathol. 2021;28(3):119-138.
- Bernthal NM, Federman N, Eilber FR, Nelson SD, Eckardt JJ, Eilber FC, et al. Long-term results (>25 years) of a randomized, prospective clinical trial evaluating chemotherapy in patients with high-grade, operable osteosarcoma. Cancer. 2012;118(23):5888-93.
- Link MP, Goorin AM, Miser AW, Green AA, Pratt CB, Belasco JB, et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med. 1986;314(25):1600-6.
- Lussier DM, Johnson JL, Hingorani P, Blattman JN. Combination immunotherapy with alpha-CTLA-4 and alpha-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma. J immunother Cancer. 2015; 3(21).
- Chen C, Xie L, Ren T, Huang Y, Xu J, Guo W. Immunotherapy for osteosarcoma: Fundamental mechanism, rationale, and recent breakthroughs. Cancer Lett. 2021;500:1-10.
- Shoaib Z, Fan TM, Irudayaraj JMK. Osteosarcoma mechanobiology and therapeutic targets. Br J Pharmacol. 2022;179(2):201-217.
- Brown HK, Tellez-Gabriel M, Heymann D. Cancer stem cells in osteosarcoma. Cancer Lett. 2017;386:189-195.
- Bozkurt, AS. Publication status of mouse embryonic fibroblast cells in scientific journals. European Journal of Therapeutics.2021;27(2):135–141.
- Van Eck, NJ, Waltman L. (2014). Visualizing Bibliometric Networks. In: Ding, Y., Rousseau, R., Wolfram, D. (eds) Measuring Scholarly Impact. Springer, Cham.
- Yin MC, Wang HS, Yang X, Xu CQ, Wang T, Yan YJ, et al. Bibliometric Analysis and Visualization of Current Research Trends in Chinese Medicine for Osteosarcoma. Chin J Integr Med. 2022;28(5):445-452.